Statement: The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event.
Primary_evidence: Adverse Events 1:   Total: 8/29 (27.59%)   Leukopenia  [1]1/29 (3.45%)   Thrombocytopenia  [1]1/29 (3.45%)   Abscess  [1]1/29 (3.45%)   Breast Abscess 1/29 (3.45%)   Fever/Sepsis  [1]1/29 (3.45%)   Neutropenic Fever  [2]1/29 (3.45%)   Peripheral Neuropathy  [1]1/29 (3.45%)   Seizure/Syncope  [1]1/29 (3.45%)   Hematuria  [1]1/29 (3.45%)   UTI  [1]1/29 (3.45%)   Shortness of breath  [1]1/29 (3.45%)
Secondary_evidence: Adverse Events 1:   Total: 7/9 (77.78%)   Febrile Neutropenia1/9 (11.11%)   Neutropenia1/9 (11.11%)   Tachycardia1/9 (11.11%)   Hematemesis1/9 (11.11%)   Small Bowel Obstruction1/9 (11.11%)   Pneumonia1/9 (11.11%)   Hypokalemia1/9 (11.11%)   Alcohol Poisoning1/9 (11.11%)   Progressive Disease4/9 (44.44%)